The ABR Knockout HT29 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colon adenocarcinoma epithelial cell line, engineered to carry targeted disruptions in the ABR gene. This loss-of-function model enables the study of ABR-dependent signaling and cellular behaviors without the selection of individual clonal isolates, preserving population-level heterogeneity. The polyclonal nature facilitates the assessment of ABR deficiency across a diverse genetic background, providing a robust tool for functional genomics and cancer research applications.
The HT29 host cell line was originally isolated from a 44-year-old female with colorectal adenocarcinoma and exhibits epithelial morphology with the capacity to form polarized monolayers. These cells express characteristic intestinal markers and are widely employed as a model system for investigating colorectal adenocarcinoma biology, intestinal epithelial barrier function, and drug transport mechanisms. Their well-characterized growth properties and suitability for a range of in vitro assays make HT29 cells an ideal platform for gene knockout studies aimed at dissecting molecular pathways relevant to colon cancer and inflammatory conditions.
The ABR protein functions as a dual RhoGAP and RhoGEF, but its primary role in this context is as a GTPase-activating protein (GAP) for the small GTPases Rac1 and Cdc42. ABR accelerates the intrinsic GTP hydrolysis of active Rac1 and Cdc42 to their inactive GDP-bound states, thereby downregulating downstream effectors such as PAK1, WASP/WAVE, and the Arp2/3 complex, ultimately leading to reduced actin polymerization and attenuated cell migration. Upstream regulators of ABR include epidermal growth factor (EGF), platelet-derived growth factor (PDGF), integrin engagement, and phosphoinositide 3-kinase (PI3K) signaling. ABR also interacts with TSC1 (hamartin) and TSC2 (tuberin), and its function is modulated by 14-3-3 proteins, integrating growth factor and adhesion cues with cytoskeletal dynamics.
In HT29 colon adenocarcinoma cells, ablation of ABR is expected to perturb the balance of Rho GTPase activity, leading to enhanced Rac1 and Cdc42 signaling, increased PAK-mediated phosphorylation of LIM kinase and cofilin, and altered actin cytoskeleton organization. These molecular changes can manifest as modified cell-matrix adhesion, elevated migratory and invasive capacity, and potential disruption of epithelial barrier integrity. Given the role of ABR as a negative regulator of inflammatory signaling, its knockout may further impact cytokine responses and intercellular junction stability, making this model highly relevant for studying the mechanisms underlying colorectal adenocarcinoma progression, metastasis, and inflammation-associated carcinogenesis.
This polyclonal knockout cell population supports a variety of advanced research applications, including quantitative analysis of Rac1/Cdc42 activity through GTPase activation assays, visualization of F-actin redistribution by immunofluorescence, and functional assessment of cell migration using Transwell invasion chambers. It is particularly suited for investigating the ABR-mediated regulation of focal adhesion dynamics and leukocyte transendothelial migration in the context of colorectal adenocarcinoma. Additional applications encompass transcriptomic profiling by RNA-seq to identify ABR-dependent gene networks, co-immunoprecipitation studies of the TSC1-TSC2 complex, and measurement of transepithelial electrical resistance (TEER) to evaluate barrier function. For further technical details and support regarding this product, please contact Ascent Research.
